---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-25-000020"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T12:48:08.869873+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ligand subsidiary Pelthos to merge with Channel Therapeutics; $50M capital raise

## Summary
- Channel to acquire 100% of Pelthos; combined company renamed Pelthos Therapeutics, listing as PTHS on NYSE American.
- Total $50M equity raised: $18M from Ligand, $32M from Murchinson-led investor group.
- Ligand retains 13% royalty on worldwide sales of ZELSUVMI, FDA-approved for Molluscum contagiosum.
- Scott Plesha to become CEO, Frank Knuettel CFO; board includes two Ligand appointees.
- Transaction expected to close summer 2025, subject to customary conditions.

## SEC filing metadata
- accession: 0000886163-25-000020
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/0000886163-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616325000020/lgnd-20250416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-25-000020
- JSON: https://secwatch.observer/filing/0000886163-25-000020.json
- Plain text: https://secwatch.observer/filing/0000886163-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.